Address: ‘The View’, 2nd Floor,
165, Dr. Annie Besant Road
Worli, Mumbai 400 018,India
Tel: +91-22-24941414
Web: http://www.rocheindia.com/
In November 1957, F. Hoffmann-La Roche Ltd. (FHLR), Basle, finalised negotiations with the Government of India for the local manufacture of synthetic Vitamin A and pharmaceutical specialties in line with the Indian Government’s policy of industrialisation.
The activities of Roche in India commenced with the import of finished pharmaceutical products and bulk vitamins by Volkart Brothers and subsequently by Voltas Ltd. Later the manufacture of two pharmaceutical specialties -SARIDON® and SIROLIN® commenced after an Indian Roche entity was incorporated on 1st April, 1958.
Roche Products (India) Pvt. Ltd. (formerly known as Roche Scientific Company (India) Pvt. Ltd.) was incorporated in India in April, 1994 and is an affiliate of FHLR.
FHLR initially appointed Nicholas Piramal India Ltd. (NPIL) in 1994 as authorised Distributor in India for some products of Roche. However, thereafter FHRL has appointed a new Distributor in India viz. Taksal Pharma Pvt. Ltd. (Taksal) for distribution of FHLR products in India since 2003,
Presently, Roche Products (India) Pvt. Ltd. is involved in marketing and scientific promotion of Roche’s products (including its strong biotech range) in India such as Herceptin® Mabthera® AvastinTM Pegasys® Mircera® Actemra® Valcyte® Xeloda® Tarceva® NeoRecormon® Neulastim® Neupogen® Roferon-A®, Bondronat® Cellcept® Invirase® for which Taksal Pharma Pvt. Ltd. is the authorised Importer and Distributor of FHLR in India. In addition, Xenical is imported, distributed and marketed in India by USV Limited.
Roche Products (India) Pvt. Ltd. is also actively involved in monitoring and support of various clinical trials in the field of Oncology, Nephrology, Rheumatology and Virology.
FLHR has also given perpetual license to Piramal Healthcare Limited (PHL) to use its trademarks in India such as Bactrim®, Lariam®, Valium® Madopar®, Rocaltrol®, Rivotril® and Euglucon®. Additionally, FHLR has also transferred and assigned its trademarks in India to PHL such as Dispeptal®, Ismo®, Librax®, Librium®, Mittavin®, Paraxin® and Bezalip®.
There is no doubt that India has become a country of rising opportunities. Can you first elaborate how important India has become for the Group worldwide? India has become very…
Pharmexcil’s Ravi Uday Bhaskar discusses how Indian pharma is rebuilding global confidence in its exports via a focus on quality, expanding into high-potential new markets like those in Latin America,…
Vikrant Shrotiya outlines how Novo Nordisk’s phenomenal recent global performance in obesity and diabetes has played out in India and the relevance of India to the global group. He also…
The Bombay Chamber of Commerce, established in 1836, played a key role in India’s industrial and infrastructural development during British rule and has since evolved into a professional organization with…
Drawing on over 30 years of industry experience across a wide range of global markets, Pierre Perez today adopts an open-minded approach to leading Servier’s operations in India. Having fostered…
Managing director & CEO of Ferring India, Sudheendra Kulkarni, whose responsibilities have grown to cover the entire 10-country South Asia & ASEAN cluster, speaks about Ferring’s Indian footprint, which includes…
KV Subramaniam, president of Reliance Life Sciences, a research-driven medical biotech with a fully integrated value chain that covers everything from research to manufacturing, comments on the firm’s unique positioning…
Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader…
In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO…
Director of the oldest and largest cancer centre in India, the Tata Memorial Hospital, C S Pramesh also heads up the National Cancer Grid (NCG), a nationwide network of over…
Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the…
Ayushman Bharat, launched in 2018, is a monumental scheme addressing the lack of healthcare accessibility and affordability for over 500 million people in India. Dr Indu Bhushan, Ayushman Bharat’s inaugural…
India’s chemical industry is of vital importance to several industries, including pharmaceuticals, and exported USD 30.18 billion worth of products in 2022-23. Chemexcil’s Raghuveer Kini discusses his industry’s key role…
See our Cookie Privacy Policy Here
